ISSN 2107-0180, 0378-7966
5 papers in the library · 57 citations · publishing 1982-2026
European Journal of Drug Metabolism and Pharmacokinetics August 28, 2026
Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.
European Journal of Drug Metabolism and Pharmacokinetics April 30, 2024 L. T. van der Heijden, F. Opdam, J. H. Beijnen et al.
Cytochrome P450 (CYP) enzymes play a central role in the elimination of approximately 80% of all clinically used drugs. Differences in CYP enzyme activity between individuals can contribute to interindividual variability in exposure and, therefore, treatment outcome. In vivo CYP enzyme activity could be determined with phenotyping. Currently, (sub)therapeutic doses are used for in vivo...
European Journal of Drug Metabolism and Pharmacokinetics May 1, 2023 Meghan Good, Zelah Joel, Tiffanie Benway et al. 54 citations
N,N-dimethyltryptamine (DMT) is a psychedelic compound under development for the treatment of major depressive disorder (MDD). This study evaluated the preclinical and clinical pharmacokinetics and metabolism of DMT in healthy subjects. The physiochemical properties of DMT were determined using a series of in vitro experiments and its metabolic profile was assessed using monoamine oxidase (MAO)...
European Journal of Drug Metabolism and Pharmacokinetics October 1, 1984 N S Shah, O D Gulati
Levels of unchanged mescaline were examined in the plasma and brain of albino Swiss-Webster mice pretreated with various doses of either clozapine or molindone. In clozapine treated mice, the mescaline levels were statistically significantly higher at 2 and 3 h with 7.5 and 15.0 mg/kg and at 1, 2 and 3 h with 30 mg/kg. Molindone at 4.0 and 8.0 mg/kg produced no significant effect; at 16.0 and...
European Journal of Drug Metabolism and Pharmacokinetics 1982 C. Van Peteghem, A. Heyndrickx, W. Van Zele 3 citations
By means of a highly specific and sensitive mass fragmentographic method mescaline was measured in rabbit plasma samples, taken at various points after an i.v. injection. The pharmacokinetic behaviour conformed to the two-compartment open model. Half-life times of alpha and beta phases, velocity constants and steady-state distribution volumes of four subjects are reported.